Annals of medicine and surgery (2012) · 2024
Guillain-Barre syndrome following Pfizer-BioNTech (BNT162b2) vaccination: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chaudhary Aashutosh, Khadka Shrekshya, Dulal Aliza, Adhikari Rojeena, Bhardwaj Sushant, Pandey Abhishek, Chaudhary Ashlesha, Bhusal Suzit, Acharya Smriti
Аннотация
INTRODUCTION: Pfizer-BioNTech (BNT162b2) is one of the mRNA vaccines currently approved by the WHO and the Food and Drug Administration (FDA) against COVID-19.
CASE PRESENTATION: Here, the authors report a case of an 8-year-old female with Guillain-Barré syndrome following the second dose of Pfizer-BioNTech (BNT162b2) vaccination requiring respiratory support who was managed with intravenous immunoglobulin.
DISCUSSION: There have been reports of Guillain-Barré syndrome following the Pfizer-BioNTech vaccination. In the authors' case, as the symptoms of Guillain-Barré syndrome occurred right after the vaccination, there could be an association, and this report can add to the existing literature and raise awareness about the possible adverse effects of the Pfizer-BioNTech vaccination.
CONCLUSION: Although most adverse effects following Pfizer-BioNTech (BNT162b2) vaccination have been reported as non-serious, clinicians must be aware of serious adverse effects that, although rare, can follow the administration of Pfizer-BioNTech vaccination and require prompt recognition and management.
CASE PRESENTATION: Here, the authors report a case of an 8-year-old female with Guillain-Barré syndrome following the second dose of Pfizer-BioNTech (BNT162b2) vaccination requiring respiratory support who was managed with intravenous immunoglobulin.
DISCUSSION: There have been reports of Guillain-Barré syndrome following the Pfizer-BioNTech vaccination. In the authors' case, as the symptoms of Guillain-Barré syndrome occurred right after the vaccination, there could be an association, and this report can add to the existing literature and raise awareness about the possible adverse effects of the Pfizer-BioNTech vaccination.
CONCLUSION: Although most adverse effects following Pfizer-BioNTech (BNT162b2) vaccination have been reported as non-serious, clinicians must be aware of serious adverse effects that, although rare, can follow the administration of Pfizer-BioNTech vaccination and require prompt recognition and management.